Analytical Data
-
基因名
CDKN2AIPNL
- Application
-
别名
CDKN2A-interacting protein N-terminal-like protein
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96HQ2
-
表达区间
1-116aa
-
分子量
17.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDKN2AIPNL (Cyclin Dependent Kinase Inhibitor 2A Interacting Protein N-terminal Like) is a relatively newly identified gene that has attracted attention due to its potential involvement in cell cycle regulation and cancer progression. Although the precise biological function of CDKN2AIPNL remains under investigation, it has been linked to the regulation of cell proliferation and survival in various organisms. Research suggests that it may interact with key cell cycle regulators, including cyclin-dependent kinases (CDKs), thereby influencing cellular response to stress and unregulated growth. Given the significance of the CDKN2A gene family in tumor suppression, understanding CDKN2AIPNL’s role offers insights into potential therapeutic avenues for cancer treatment. Recombinant protein studies of CDKN2AIPNL are essential to elucidate its functional characteristics, interaction partners, and the mechanisms by which it may affect oncogenic pathways. Thus, generating and characterizing recombinant CDKN2AIPNL proteins will contribute to a functional understanding of this gene and its implications in cancer biology, potentially paving the way for novel therapeutic strategies targeting cell cycle dysregulation.
